Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Mustafa Nuri Yenerel, Arpad Illés, Neil Kay, Jose A. Garcia-Marco, Anthony Mato, Javier Pinilla-Ibarz, John F. Seymour, Stephane Lepretre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed HamdyPriti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak

Hematology / Oncology / Cancer Center / Breast Clinic
Hematology

Research output: Contribution to journal › Article › peer-review

Sort by
Weight
Alphabetically

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Fingerprint

Medicine & Life Sciences